BofA Securities has expressed confidence in the ongoing recovery of medical equipment manufacturer Smith & Nephew, headquartered on the New York Stock Exchange (NYSE: SNN), by increasing its price target on the company's shares.
The target was raised to $39.00, up from the previous target, while the firm maintained a Buy rating on the stock.
The analyst at BofA Securities highlighted several factors contributing to the positive outlook for Smith & Nephew. The report indicated signs of improvement in the US Orthopedics sector, which is a key market for the company.
Additionally, the firm is increasingly confident in the company's margin outlook for the fiscal year 2025 and beyond, citing new opportunities for savings that have been identified.
The report also pointed to potential upside from improvements in cash flow. Even after a 25% increase in share price performance, the analyst believes that Smith & Nephew's valuation remains attractive when compared to its peers.
The valuation is based on a 14 times calendar year 2025 estimated price-to-earnings (P/E) ratio, which is seen as favorable given the company's earnings growth and returns.
The revised price objective represents a total shareholder return (TSR) of 25%. This adjustment is based on better cash flow assumptions in the firm's discounted cash flow (DCF) analysis. The new price target of $39.00, equivalent to £14.7 for the American Depositary Receipt (ADR), reflects an increase from the previous target of £13.7.
In other recent news, medical equipment manufacturer Smith & Nephew reported a robust second quarter, marked by a 5.6% revenue increase and an expansion of the operating margin by 140 basis points. This growth was largely driven by the Sports Medicine and Advanced Wound Management segments. The company also noted geographical growth led by emerging markets, which saw a 9.5% increase, and steady growth in the U.S. and other established markets.
Smith & Nephew has projected a full-year revenue growth of between 5% and 6%, with a focus on enhancing cash generation and capital allocation. The firm is targeting a trading cash conversion of around 85% and reported positive free cash flow of $39 million. The company maintains a full-year trading margin guidance of at least 18% and is confident in achieving a 2025 margin target of at least 20%.
In the face of a 130 basis points margin headwind in the second half of 2024 due to China VBP, the company has planned actions to mitigate this impact in 2025. The company's 12-Point Plan is showing positive indicators such as deal activity and improved capital efficiency.
InvestingPro Insights
With Smith & Nephew's recent positive assessment from BofA Securities, the company's financial health and market performance provide additional context for investors. According to InvestingPro data, Smith & Nephew is trading at a high earnings multiple, with a current P/E ratio of 43.68, which adjusts to 24.64 when looking at the last twelve months as of Q2 2024. This is in line with the analyst's view that the company's valuation remains attractive despite a significant P/E ratio. The company's commitment to shareholder returns is evident through its impressive track record of maintaining dividend payments for 48 consecutive years, and its dividend yield stands at 1.9% as of the latest data.
Investors may also take note of Smith & Nephew's stock performance, which has shown strong returns over the last three months, with a 16.68% price total return. This aligns with the upward price target adjustment and the optimism surrounding the stock. Moreover, the company is trading near its 52-week high, at 98.27% of the peak value, reflecting investor confidence and the stock's robust performance.
For those seeking a deeper dive into Smith & Nephew's prospects, InvestingPro offers additional insights, with 9 tips currently available. These include expectations of net income growth this year and an analysis of the stock's low price volatility, which may appeal to risk-averse investors. To explore these insights further, investors can visit InvestingPro's dedicated page for Smith & Nephew at https://www.investing.com/pro/SNN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.